Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. Issue 2 (August 2015)

• Record Type: Journal Article
• Authors: Chen, Yu-Pei; Sun, Ying; Chen, Lei; Mao, Yan-Ping; Tang, Ling-Long; Li, Wen-Fei; Liu, Xu; Zhang, Wen-Na; Zhou, Guan-Qun; Guo, Rui; Lin, Ai-Hua; Ma, Jun
• Is Part Of: Radiotherapy and oncology. Volume 116:Issue 2(2015:Aug.)
• Page Start: 157
• Page End: 166
• Publication Date: 2015-08
• Subjects: Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.07.030
• Languages: English
• ISSNs: 0167-8140

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st005">Abstract</title> <sec> <title id="st010">Background and purpose</title> <p id="sp0005">We used a literature-based meta-analysis to assess whether failure-free survival (FFS) or progression-free survival (PFS) could be reliable surrogate endpoints for overall survival (OS) in trials of combined chemotherapy and radiotherapy for nasopharyngeal carcinoma (NPC).</p> </sec> <sec> <title id="st015">Methods and materials</title> <p id="sp0010">We identified randomised trials that evaluated combined chemoradiotherapy strategies, and reported FFS or PFS and OS in NPC. We analysed the treatment effects on FFS or PFS, and OS. We used the coefficient of determination (<italic>R</italic><sup>2</sup>), and the surrogate threshold effect (STE) to assess the trial-level correlation.</p> </sec> <sec> <title id="st020">Results</title> <p id="sp0015">Twenty-one trials (5212 patients), with sixteen treatment-control comparisons for FFS, and nine for PFS, were analysed. FFS was strongly correlated with OS (<italic>R</italic><sup>2</sup> = 0.88, STE = 0.84), as was PFS (<italic>R</italic><sup>2</sup> = 0.90, STE = 0.88). Moreover, FFS and PFS at 3 years were still strongly correlated with 5-year OS (<italic>R</italic><sup>2</sup> = 0.80, STE = 0.83; <italic>R</italic><sup>2</sup> = 0.85, STE = 0.84).</p> </sec> <sec> <title id="st025">Conclusions</title> <p id="sp0020">Both FFS and PFS could be valid surrogate endpoints for OS in trials of combined chemotherapy and radiotherapy for NPC; PFS may be a more acceptable surrogate endpoint compared with FFS.</p> </sec> </abstract>